EDIT Editas Medicine, Inc.

Price Chart

Executive Summary

Editas Medicine is conducting a dilutive underwritten public offering of common stock (and/or pre-funded warrants in lieu thereof) paired with common stock warrants, with Cantor Fitzgerald and Wells Fargo Securities as joint bookrunners. The offering is a preliminary prospectus supplement with all key financial terms (share count, price, net proceeds) left as placeholders, indicating pricing is not yet set. Proceeds are earmarked for advancing lead candidate EDIT-401 (in vivo gene editing for hyperlipidemia) through clinical development and manufacturing, plus working capital. The filing is unambiguously bearish: a pre-revenue biotech with $123.6M cash is tapping the equity markets for additional capital, causing immediate and future dilution to existing shareholders.

Actionable Insight

Key Facts

• Editas is offering an undisclosed number of common shares (and/or pre-funded warrants) plus accompanying common stock warrants in a firm-commitment underwritten offering.
• The common stock warrants have a 3-year term and expire 30 days after announcement of Phase 1 EDIT-401 data showing >80% LDL-C reduction in ≥3 patients with ≥1 month follow-up.
• As of March 31, 2026, Editas had $123.6M in cash and cash equivalents; net tangible book value was $4.4M ($0.05/share).
• The company had 97,906,282 shares outstanding as of April 30, 2026, and an additional $106.1M available under its ATM program with TD Securities.
• Proceeds will fund EDIT-401 clinical development and manufacturing, plus working capital; management has broad discretion over allocation.
• The filing is a preliminary prospectus supplement — all dollar amounts, share counts, and net proceeds are placeholder values (TBD).

Financial Impact

Dilutive equity offering of undisclosed size; net tangible book value was $4.4M ($0.05/share) pre-offering; immediate and substantial dilution expected for new investors.

Risk Factors

• Immediate and substantial dilution to existing shareholders from the offering itself.
• Future dilution from exercise of common stock warrants (3-year term, contingent on EDIT-401 Phase 1 data).
• EDIT-401 is pre-clinical; clinical failure would render the capital raise value-destructive.
• Management has broad discretion over use of proceeds; no specific allocation disclosed.
• No public market for the warrants; they are illiquid and speculative.
• Company has $106.1M ATM capacity that could add further dilution.

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status